RESUMO
OBJECTIVES: To evaluate the influence of the SARS-CoV-2 pandemic on the adherence of patients with inflammatory rheumatic diseases (IRD) to their immunomodulatory medication during the three-month lockdown in Germany. METHODS: From 16th March until 15th June 2020, IRD patients from private practices and rheumatology departments were asked to answer a questionnaire addressing their behaviour with respect to their immunomodulating therapy. Eight private practices and nine rheumatology departments that included rheumatology primary care centres and university hospitals participated. A total of 4252 questionnaires were collected and evaluated. RESULTS: The majority of patients (54%) were diagnosed with RA, followed by psoriatic arthritis (14%), ankylosing spondylitis (10%), connective tissue diseases (12%) and vasculitides (6%). Most of the patients (84%) reported to continue their immunomodulatory therapy. Termination of therapy was reported by only 3% of the patients. The results were independent from the type of IRD, the respective immunomodulatory therapy and by whom the patients were treated (private practices vs rheumatology departments). Younger patients (<60 years) reported just as often as older patients to discontinue their therapy. CONCLUSION: The data show that most of the patients continued their therapy in spite of the pandemic. A significant change in behaviour with regard to their immunomodulatory therapy was not observed during the three months of observation. The results support the idea that the immediate release of recommendations of the German Society of Rheumatology were well received, supporting the well-established physician-patient relationship in times of a crisis.
Assuntos
COVID-19/prevenção & controle , Prescrições de Medicamentos/estatística & dados numéricos , Adesão à Medicação/estatística & dados numéricos , Padrões de Prática Médica/estatística & dados numéricos , Quarentena/estatística & dados numéricos , Doenças Reumáticas/tratamento farmacológico , Adulto , Antirreumáticos/uso terapêutico , Estudos Transversais , Feminino , Alemanha , Humanos , Fatores Imunológicos/uso terapêutico , Masculino , Pessoa de Meia-Idade , SARS-CoV-2RESUMO
The current COVID-19 pandemic inherits an unprecedented challenge for the treating rheumatologists. On the one hand, antirheumatic drugs can increase the risk of infection and potentially deteriorate the course of an infection. On the other hand, an active inflammatory rheumatic disease can also increase the risk for an infection. In the recommendations of the German Society for Rheumatology (www.dgrh.de), it is recommended that our patients continue the antirheumatic therapy to maintain remission or low state of activity despite the pandemic. In this study, patients with inflammatory rheumatic disease were asked in the first weeks of the pandemic on their opinion of their immunomodulating therapy. The result shows that over 90% of the patients followed the recommendation of the rheumatologist to continue the antirheumatic therapy, and only a small percentage of the patients terminated the therapy on their own. This result was independent of the individual anti-rheumatic therapy. Taken together, the results of this study illustrate not only the trustful patient-physician partnership in a threatening situation but also the high impact of state-of-the art recommendations by the respective scientific society.
Assuntos
Infecções por Coronavirus , Hospedeiro Imunocomprometido , Adesão à Medicação , Pandemias , Pneumonia Viral , Doenças Reumáticas/imunologia , Antirreumáticos/efeitos adversos , Antirreumáticos/uso terapêutico , Betacoronavirus , COVID-19 , Infecções por Coronavirus/epidemiologia , Infecções por Coronavirus/imunologia , Estudos Transversais , Humanos , Imunossupressores/efeitos adversos , Imunossupressores/uso terapêutico , Pneumonia Viral/epidemiologia , Pneumonia Viral/imunologia , Doenças Reumáticas/complicações , Doenças Reumáticas/tratamento farmacológico , SARS-CoV-2RESUMO
OBJECTIVE: In the general population, the incidence of stroke is increased following other serious events and hospitalisation. We investigated the impact of serious adverse events on the risk of stroke in patients with rheumatoid arthritis (RA), taking risk factors and treatment into account. METHODS: Using data of the German biologics register RABBIT (Rheumatoid Arthritis: Observation of Biologic Therapy) with 12354 patients with RA, incidence rates (IRs) and risk factors for stroke were investigated using multi-state and Cox proportional hazard models. In addition, in a nested case-control study, all patients with stroke were matched 1:2 to patients with identical baseline risk profile and analysed using a shared frailty model. RESULTS: During follow-up, 166 strokes were reported. The overall IR was 3.2/1000 patient-years (PY) (95% CI 2.7 to 3.7). It was higher after a serious adverse event (IR: 9.0 (7.3 to 11.0)), particularly within 30 days after the event (IR: 94.9 (72.6 to 121.9)). The adjusted Cox model showed increased risks of age per 5 years (HR: 1.4 (1.3 to 1.5)), hyperlipoproteinaemia (HR: 1.6 (1.0 to 2.5)) and smoking (HR: 1.9 (1.3 to 2.6)). The risk decreased with better physical function (HR: 0.9 (0.8 to 0.96)). In the case-control study, 163 patients were matched to 326 controls. Major risk factors for stroke were untreated cardiovascular disease (HR: 3.3 (1.5 to 7.2)) and serious infections (HR:4.4 (1.6 to 12.5)) or other serious adverse events (HR: 2.6 (1.4 to 4.8)). CONCLUSIONS: Incident adverse events, in particular serious infections, and insufficient treatment of cardiovascular diseases are independent drivers of the risk of stroke. Physicians should be aware that patients who experience a serious event are at increased risk of subsequent stroke.
Assuntos
Antirreumáticos/efeitos adversos , Artrite Reumatoide/tratamento farmacológico , Infecções/etiologia , Ataque Isquêmico Transitório/epidemiologia , Sistema de Registros , Acidente Vascular Cerebral/epidemiologia , Adulto , Fatores Etários , Idoso , Produtos Biológicos , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/terapia , Estudos de Casos e Controles , Cicloexanonas , Feminino , Alemanha , Humanos , Hipolipoproteinemias/epidemiologia , Hospedeiro Imunocomprometido , Incidência , Infecções/epidemiologia , Infecções/imunologia , Masculino , Pessoa de Meia-Idade , Fenóis , Modelos de Riscos Proporcionais , Fatores de Risco , Fumar/epidemiologiaRESUMO
136 patients with insulin-dependent diabetes mellitus (IDDM) were shown the entoptic blood vessel figure. All patients were examined independently by retinal fluorescein angiography and ophthalmoscopy. 34 patients had no retinopathy, none of them believed to see alterations. 102 patients had different phases of diabetic retinopathy. If there were 1-5 microaneurysms within the 15 degrees meridian surrounding the central fovea, 55% of the patients were able to detect their alterations. If there were 6-20 microaneurysms, 77% of the patients were able to diagnose them. 90% of the patients with an even more severe retinopathy could see their abnormalities. Obviously there are no incorrectly positive results. For intelligent and well-observing patients with IDDM the retinal blood vessel test is a useful method for early detection and self control of diabetic retinopathy. Nevertheless, control of the fundus by an ophthalmologist is still necessary.